Benzoyl peroxide and potassium hydroxyquinoline sulphate topical
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Topical formulations containing benzoyl peroxide and potassium hydroxyquinoline sulfate
Drugs List
Therapeutic Indications
Uses
Acne vulgaris
Superficial folliculitis: treatment
Dosage
Adults
Apply with gentle massage to the affected area 2 to 3 times a day.
Elderly
Apply with gentle massage to the affected area 2 to 3 times a day.
Children
Apply with gentle massage to the affected area 2 to 3 times a day.
Contraindications
Rosacea
Precautions and Warnings
Neonates under 1 month
Breastfeeding
Avoid applying topical preparations containing zinc oxide at the same time
Avoid contact with eyes
Avoid contact with mucous membranes
Do not apply retinoids at the same time of day
Discontinue if excessive irritation, redness or peeling occurs
Advise patient on appropriate sun protection methods
Advise patient residue on clothing/bedding may cause fire hazard
Advise patient to consult a doctor if symptoms persist despite treatment
Avoid excessive exposure to sunlight
Fire hazard: Keep away from naked flames and potential sources of ignition
Keep away from mouth
May bleach hair and fabrics
Test on a small area of skin prior to use
Pregnancy and Lactation
Pregnancy
Benzoyl peroxide and potassium hydroxyquinoline sulfate is considered safe for use in pregnancy.
Manufacturer advises the product is not contraindicated.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Lactation
Use benzoyl peroxide and potassium hydroxyquinoline sulfate with caution in breastfeeding.
There is considered to be a low risk to the infant due to the low level of absorption of benzoyl peroxide. However, the infant's skin should not come into contact with the area.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Side Effects
Dry skin
Erythema
Facial oedema
Hypersensitivity reactions
Inflammation (application site)
Irritation (localised)
Itching
Rash
Skin peeling
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: March 2016
Reference Sources
Summary of Product Characteristics: Quinoderm 10%/0.5% w/w cream. Alliance Pharmaceuticals. Revised July 2014.
Summary of Product Characteristics: Quinoderm 5%/0.5% w/w cream. Alliance Pharmaceuticals. Revised July 2014.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.